D&D Pharmatech
D&D Pharmatech Inc is a South Korean clinical-stage biopharmaceutical company focused on developing therapies for metabolic and neurodegenerative diseases. The company utilizes its proprietary peptide design and drug discovery platforms to engineer therapeutic candidates targeting Parkinson's disease, Alzheimer's disease, metabolic dysfunction-associated steatohepatitis, and obesity. Principal revenue is generated from biopharmaceutical research partnerships, upfront licensing fees, and development milestone payments. Core end markets embrace neurology clinics, endocrinology centers, and global biopharmaceutical corporations. D&D Pharmatech holds an innovative position in South Korea's biopharmaceutical sector for CNS and metabolic disease candidate pipelines. The company is headquartered in Seongnam, South Korea, and its common shares trade on the KOSDAQ market of the Korea Exchange.
2 of the funds FundTelligence covers report a position in D&D Pharmatech.
- Legal name
- D&D PHARMATECH INC
- Sector
- Health Care
- Country
- South Korea
- Funds holding it
- 2
- Exposure themes
- Incretin & GLP-1 Therapies, Obesity, Obesity & Metabolic Health
Funds holding D&D Pharmatech
- BlackRock iShares Healthcare Innovation UCITS ETF — BlackRock · 0.1 % (full portfolio disclosed, October 2026)
- BlackRock iShares MSCI EM IMI Screened UCITS ETF — BlackRock · 0.0 % (full portfolio disclosed, October 2026)